 In 2013, Bristol-Myers Squibb Co. sold its CeeNU brand of lomustine to CordenPharma, a subsidiary of International Chemical Investors S.E., which markets it as Gleostine through NextSource Biotechnology.In 2013, BMS charged $50 a capsule.In 2018, NextSource charged $768 a capsule.